Oculis Holding AG Ordinary shares Cash Flow Conversion Efficiency
Oculis Holding AG Ordinary shares cash flow conversion efficiency. Based on the latest financial reports, Oculis Holding AG Ordinary shares (OCS) has a cash flow conversion efficiency ratio of -0.081x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-15.98 Million) by net assets ($196.29 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Oculis Holding AG Ordinary shares (2020–2025)
Cash flow conversion efficiency of Oculis Holding AG Ordinary shares from 2020 to 2025. This chart illustrates how Oculis Holding AG Ordinary shares's cash flow conversion efficiency has evolved over time, based on yearly financial data. View OCS share price today for real-time trading data and today's change.
Oculis Holding AG Ordinary shares Cash Flow Conversion Ratio Explained
Oculis Holding AG Ordinary shares cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Oculis Holding AG Ordinary shares Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Oculis Holding AG Ordinary shares ranked by their cash flow conversion efficiency. Also see Oculis Holding AG Ordinary shares (OCS) total market value for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Baotou Dongbao Bio-Tech Co Ltd
SHE:300239
|
0.005x |
|
Grupo Traxión S.A.B. de C.V
MX:TRAXIONA
|
0.047x |
|
Pes Camanchaca
SN:CAMANCHACA
|
0.052x |
|
Norma Group AG NA O.N.
XETRA:NOEJ
|
0.035x |
|
Shenyang Chemical Industry Co Ltd
SHE:000698
|
0.135x |
|
Haverty Furniture Companies Inc
NYSE:HVT
|
0.104x |
|
Plaza Retail REIT
TO:PLZ-UN
|
0.017x |
|
Direct Finance TA
TA:DIFI
|
0.271x |
Annual Cash Flow Conversion Efficiency for Oculis Holding AG Ordinary shares (2020–2025)
The table below shows the annual cash flow conversion efficiency of Oculis Holding AG Ordinary shares from 2020 to 2025. Review Oculis Holding AG Ordinary shares (OCS) financial flexibility to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $196.29 Million | $-62.22 Million | -0.317x | +51.03% |
| 2024-12-31 | $73.38 Million | $-47.50 Million | -0.647x | -12.67% |
| 2023-12-31 | $93.73 Million | $-53.84 Million | -0.574x | -324.51% |
| 2022-12-31 | $-97.99 Million | $-25.07 Million | 0.256x | +12.82% |
| 2021-12-31 | $-60.95 Million | $-13.82 Million | 0.227x | -17.69% |
| 2020-12-31 | $-43.65 Million | $-12.03 Million | 0.276x | -- |
About Oculis Holding AG Ordinary shares
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic, neuro-ophthalmic, and neurological diseases in Switzerland and internationally. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candida… Read more